36 related articles for article (PubMed ID: 36649216)
1. Piceatannol selectively inhibited the JNK3 enzyme and augmented apoptosis through inhibition of Bcl-2/Cyt-c/caspase-dependent pathways in the oxygen-glucose deprived SHSY-5Y cell lines: In silico and in vitro study.
Rajan RK; Ramanathan M
Chem Biol Drug Des; 2024 Feb; 103(2):e14458. PubMed ID: 38383061
[TBL] [Abstract][Full Text] [Related]
2. Identification of potential JNK3 inhibitors through virtual screening, molecular docking and molecular dynamics simulation as therapeutics for Alzheimer's disease.
Devi B; Jangid K; Kumar N; Kumar V; Kumar V
Mol Divers; 2024 Apr; ():. PubMed ID: 38573427
[TBL] [Abstract][Full Text] [Related]
3. Novel Tryptanthrin Derivatives with Selectivity as
Schepetkin IA; Karpenko OS; Kovrizhina AR; Kirpotina LN; Khlebnikov AI; Chekal SI; Radudik AV; Shybinska MO; Quinn MT
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375361
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Pyrimidine- and Coumarin-Linked Hybrid Molecules as Inducers of JNK Phosphorylation through ROS Generation in Breast Cancer Cells.
Kim NY; Vishwanath D; Xi Z; Nagaraja O; Swamynayaka A; Kumar Harish K; Basappa S; Madegowda M; Pandey V; Sethi G; Lobie PE; Ahn KS; Basappa B
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110684
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Potent and Selective JNK3 Inhibitor with Neuroprotective Effect Against Amyloid β-Induced Neurotoxicity in Primary Rat Neurons.
Jun J; Baek J; Yang S; Moon H; Kim H; Cho H; Hah JM
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681742
[TBL] [Abstract][Full Text] [Related]
6. Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases.
Dou X; Huang H; Li Y; Jiang L; Wang Y; Jin H; Jiao N; Zhang L; Zhang L; Liu Z
J Med Chem; 2019 Jul; 62(14):6645-6664. PubMed ID: 31268308
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel imidazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Alzheimer's disease.
Jun J; Yang S; Lee J; Moon H; Kim J; Jung H; Im D; Oh Y; Jang M; Cho H; Baek J; Kim H; Kang D; Bae H; Tak C; Hwang K; Kwon H; Kim H; Hah JM
Eur J Med Chem; 2023 Jan; 245(Pt 1):114894. PubMed ID: 36343411
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective Effects of the Absence of JNK1 or JNK3 Isoforms on Kainic Acid-Induced Temporal Lobe Epilepsy-Like Symptoms.
de Lemos L; Junyent F; Camins A; Castro-Torres RD; Folch J; Olloquequi J; Beas-Zarate C; Verdaguer E; Auladell C
Mol Neurobiol; 2018 May; 55(5):4437-4452. PubMed ID: 28664455
[TBL] [Abstract][Full Text] [Related]
9. The structure-based optimization of 3-substituted indolin-2-one derivatives as potent and isoform-selective c-Jun N-terminal kinase 3 (JNK3) inhibitors and biological evaluation.
Li Z; Zhu G; Liu X; Gao T; Fang F; Dou X; Li Y; Zheng R; Jin H; Zhang L; Liu Z; Zhang L
Eur J Med Chem; 2023 Mar; 250():115167. PubMed ID: 36764123
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Indazole Chemotypes as Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease.
Shuai W; Bu F; Zhu Y; Wu Y; Xiao H; Pan X; Zhang J; Sun Q; Wang G; Ouyang L
J Med Chem; 2023 Jan; 66(2):1273-1300. PubMed ID: 36649216
[TBL] [Abstract][Full Text] [Related]
11. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
Gehringer M; Muth F; Koch P; Laufer SA
Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
[TBL] [Abstract][Full Text] [Related]
12. A Perspective on the Development of c-Jun N-terminal Kinase Inhibitors as Therapeutics for Alzheimer's Disease: Investigating Structure through Docking Studies.
Cho H; Hah JM
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680547
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
